

## **Orthocell receives WA innovation excellence award for CelGro®**

- Orthocell receives the Innovation Excellence Award for CelGro® at the 2016 Annual Western Australian Industry & Export Awards
- CelGro® is manufactured by Orthocell in Australia, and is a unique collagen medical device platform for soft tissue repair and regeneration
- Orthocell has submitted CelGro® for first regulatory approval in Europe

**Perth, Australia; 31<sup>st</sup> October 2016:** Regenerative medicine company Orthocell is pleased to announce the Company has received the Innovation Excellence Award at the 2016 Annual Western Australian Industry & Export Awards for the development of CelGro® a collagen based medical device platform to enhance soft tissue repair and regeneration.

The Innovation Excellence Award is, “for outstanding achievement or excellence in developing an innovative commercial product, process, service or technology. The Innovation Excellence Award recognizes business that are contributing to the advancement of the economy through their innovation.” The finalists for this award category were Austal Ltd, Proteomics International Pty and Orthocell Ltd.

CelGro® is a biological medical device used as a scaffold for a variety of orthopaedic and general reconstructive surgical applications. Orthocell is undertaking clinical studies using CelGro® to augment repair of the rotator cuff tendon within the shoulder, as an augment to guide and promote bone regeneration, as well as an augment to cartilage repair within the hip joint and peripheral nerve repair.

Orthocell Managing Director Paul Anderson said; “Celgro is an exciting, globally relevant platform technology with many applications and enormous potential. This award recognizes the quality of the CelGro® platform and the effort of the team at Orthocell in its development”.

Orthocell has submitted CelGro® for regulatory approval in Europe for ‘Guided bone regeneration and soft tissue reconstruction’. Receipt of this approval will enable sales of CelGro® to commence in Europe, and trigger applications for other regulatory approvals in the United States, Australia and Japan in 2017.

-ENDS



**For more information, please contact:**



**General enquiries**

**Paul Anderson**  
**Orthocell Limited, Managing Director**

P: +61 8 9360 2888  
E: paulanderson@orthocell.com.au

**Investor and Media enquiries**

**Ben Walsh**  
**WE Buchan**

P: + 61 411 520 012  
E: bwalsh@buchanwe.com.au

**About Orthocell Limited**

Orthocell is a commercial-stage, regenerative medicine company focused on regenerating mobility for patients and our ageing population by developing products for a variety of tendon, cartilage and soft tissue injuries. Orthocell's portfolio of products include TGA-approved stem cell therapies Autologous Tenocyte Implantation (Ortho-ATI™) and Autologous Chondrocyte Implantation (Ortho-ACI™), which aim to regenerate damaged tendon and cartilage tissue. The Company's other major product is Celgro™, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approvals.

Ph: +61 8 9360 2888 Fax: +61 8 9360 2899 [www.orthocell.com.au](http://www.orthocell.com.au)

